Title:
METHOD FOR PREPARING EGFR-MOLECULE-TARGETED ANTI-TUMOR DRUG
Document Type and Number:
WIPO Patent Application WO/2023/155321
Kind Code:
A1
Abstract:
The present invention relates to the technical field of anti-tumor drug preparation, and particularly relates to a method for preparing an EGFR-molecule-targeted anti-tumor drug. With regard to the problem of the drug effect being low due to the fact that the preparation technology of currently existing molecule-targeted anti-tumor drugs is still simple, the following scheme is proposed, which scheme comprises the following steps: S1: preparing raw materials and preparing a drug; S2: inspecting the drug; S3: performing a drug trial; S4: performing a therapeutic treatment; and S5: performing a subsequent treatment. The present invention aims to recycle drugs failing to meet drug quality standards by means of inspecting drugs during the drug preparation process, so as to make produced drugs all have sufficient drug properties. Moreover, the present invention aims to increase the tumor cell clearance rate of drugs and enhance drug performance by means of trialing drugs.
Inventors:
LI XIAOWEI (CN)
Application Number:
PCT/CN2022/094837
Publication Date:
August 24, 2023
Filing Date:
May 25, 2022
Export Citation:
Assignee:
SHANGHAI LONGXIANG BIO MEDICINE DEV CO LTD (CN)
International Classes:
A61K31/519; A61K9/20; A61P35/00
Foreign References:
| CN114504577A | 2022-05-17 | |||
| CN103784412A | 2014-05-14 |
Other References:
ZHANG, LI ET AL.: "Long Term Survival of a Patient with Advanced Non-small Cell Lung Cancer Under Icotinib Therapy", CHINESE JOURNAL OF NEW DRUGS, vol. 22, no. 12, 31 December 2013 (2013-12-31), pages 1435 - 1437, XP093085189
ZHE SONG, HU YI: "Clinical Analysis of Icteninib Hydrochloride in the Treatment of Advanced Non-small Cell Lung Cancer with Definite EGFR Mutation Status", CHINA & FOREIGN MEDICAL TREATMENT, vol. 37, no. 21, 3 September 2018 (2018-09-03), pages 90 - 92, XP093085190, ISSN: 1674-0742, DOI: 10.16662/j.cnki.1674-0742.2018.21.090
ZHE SONG, HU YI: "Clinical Analysis of Icteninib Hydrochloride in the Treatment of Advanced Non-small Cell Lung Cancer with Definite EGFR Mutation Status", CHINA & FOREIGN MEDICAL TREATMENT, vol. 37, no. 21, 3 September 2018 (2018-09-03), pages 90 - 92, XP093085190, ISSN: 1674-0742, DOI: 10.16662/j.cnki.1674-0742.2018.21.090
Attorney, Agent or Firm:
HANGZHOU CRESUN INTELLECTUAL PROPERTYAGENCY CO., LTD. (CN)
Download PDF:
Previous Patent: METHOD FOR SYNTHESIZING ANTI-TUMOR DRUG AFATINIB
Next Patent: FLEXIBLE EXOSKELETON FOR WORKING AT HEIGHTS
Next Patent: FLEXIBLE EXOSKELETON FOR WORKING AT HEIGHTS